Why Is Biodexa (BDRX) Up 70% Today?

Oncology specialist Biodexa (NASDAQ:BDRX) soared on Friday as the company disclosed the entering of an exclusive worldwide license to develop and commercialize a key therapeutic. Fundamentally, the announcement sent BDRX stock flying up about 70% in the late afternoon session as the drug addresses a disease for which there are no approved therapeutic options.According to a Seeking Alpha report, Biodexa inked a deal with Rapamycin Holdings, which does business as Emtora Biosciences. The licensing centers on ...